$ANEB
Anebulo Pharmaceuticals, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224045151 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.097M $1.273M
YoY Change -13.84% -8.27%
% of Gross Profit
Research & Development $1.315M $1.270M
YoY Change 3.51% 3.8%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.412M $2.544M
YoY Change -5.17% -2.62%
Operating Profit -$2.412M -$2.544M
YoY Change -5.17% -2.62%
Interest Expense -$33.69K $55.20K
YoY Change -161.03%
% of Operating Profit
Other Income/Expense, Net $211.4K $62.86K
YoY Change 236.31% 29830.95%
Pretax Income -$2.201M -$2.481M
YoY Change -11.29% -5.02%
Income Tax
% Of Pretax Income
Net Earnings -$2.200M -$2.500M
YoY Change -12.0% -4.28%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08 -$0.10
Diluted Earnings Per Share -$0.08 -$0.10
COMMON SHARES
Basic Shares Outstanding 25.93M shares 25.93M shares 25.63M shares
Diluted Shares Outstanding 25.93M shares 25.63M shares

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.404M $8.521M
YoY Change -83.52% -55.65%
Cash & Equivalents $1.404M $8.521M
Short-Term Investments
Other Short-Term Assets $312.9K $527.3K
YoY Change -40.65% -12.36%
Inventory
Prepaid Expenses $312.9K $527.3K
Receivables
Other Receivables
Total Short-Term Assets $1.963M $9.048M
YoY Change -78.31% -54.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K
YoY Change
Total Long-Term Assets $505.4K $4.00
YoY Change 12635575.0% -180.0%
TOTAL ASSETS
Total Short-Term Assets $1.963M $9.048M
Total Long-Term Assets $505.4K $4.00
Total Assets $2.468M $9.048M
YoY Change -72.72% -54.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $252.1K $565.9K
YoY Change -55.45% 8.11%
Accrued Expenses $317.1K $150.6K
YoY Change 110.53% -13.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $569.2K $716.6K
YoY Change -20.56% 2.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $569.2K $716.6K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $569.2K $716.6K
YoY Change -20.56% 2.63%
SHAREHOLDERS EQUITY
Retained Earnings -$67.60M -$59.70M
YoY Change 13.23% 24.16%
Common Stock $25.93K $25.63K
YoY Change 1.17% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.899M $8.331M
YoY Change
Total Liabilities & Shareholders Equity $2.468M $9.048M
YoY Change -72.72% -54.34%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$2.200M -$2.500M
YoY Change -12.0% -4.28%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.690M -$2.727M
YoY Change -38.02% 34.07%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$1.690M -$2.727M
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -$1.690M -$2.727M
YoY Change -38.02% -158.45%
FREE CASH FLOW
Cash From Operating Activities -$1.690M -$2.727M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2024Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78734
CY2024Q3 dei City Area Code
CityAreaCode
(512)
CY2024Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q3 dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25933217 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1404211 usd
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25933217 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25933217 shares
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1097265 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1273458 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2412124 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2543678 usd
CY2024Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q3 dei Entity File Number
EntityFileNumber
001-40388
CY2024Q3 dei Entity Registrant Name
EntityRegistrantName
ANEBULO PHARMACEUTICALS, INC.
CY2024Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1170950
CY2024Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
1017 Ranch Road 620 South
CY2024Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 107
CY2024Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Lakeway
CY2024Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2024Q3 dei Local Phone Number
LocalPhoneNumber
598-0931
CY2024Q3 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q3 dei Trading Symbol
TradingSymbol
ANEB
CY2024Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2025
CY2024Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001815974
CY2024Q2 us-gaap Grants Receivable
GrantsReceivable
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
CY2023Q3 ANEB Grant Income Other
GrantIncomeOther
usd
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
usd
CY2023Q3 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
usd
CY2024Q3 dei Document Type
DocumentType
10-Q
CY2024Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q3 dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2024Q3 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3094200 usd
CY2024Q3 us-gaap Grants Receivable
GrantsReceivable
245362 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
312940 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
413790 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
1962513 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
3507990 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
505427 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
565124 usd
CY2024Q3 us-gaap Assets
Assets
2467940 usd
CY2024Q2 us-gaap Assets
Assets
4073114 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
252142 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
156426 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
317083 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
104157 usd
CY2024Q3 us-gaap Liabilities
Liabilities
569225 usd
CY2024Q2 us-gaap Liabilities
Liabilities
260583 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25933217 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25933217 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
25934 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
25934 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69477261 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69190341 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67604480 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65403744 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
1898715 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3812531 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2467940 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4073114 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1314859 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1270220 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2412124 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2543678 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
59697 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
26006 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
55198 usd
CY2024Q3 ANEB Grant Income Other
GrantIncomeOther
245362 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-283 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7657 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
211388 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
62855 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2200736 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2480823 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25933217 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25933217 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25633217 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25633217 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10601350 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
210797 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2480823 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8331324 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3812531 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3812531 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
286920 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2200736 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
1898715 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
1898715 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2200736 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2480823 usd
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
286920 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
210797 usd
CY2024Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
59697 usd
CY2024Q3 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
245362 usd
CY2024Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-100850 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
104558 usd
CY2024Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
95716 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31404 usd
CY2024Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
212926 usd
CY2023Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-383645 usd
CY2024Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1689989 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2726825 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1689989 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2726825 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3094200 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11247403 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1404211 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8520578 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2200000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67600000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
155507 usd
CY2024Q2 us-gaap Prepaid Insurance
PrepaidInsurance
95871 usd
CY2024Q3 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
118893 usd
CY2024Q2 ANEB Prepaid Research And Development
PrepaidResearchAndDevelopment
274879 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
38540 usd
CY2024Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
43040 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
312940 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
413790 usd
CY2024Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
32843 usd
CY2024Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
29512 usd
CY2024Q3 ANEB Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
248685 usd
CY2024Q2 ANEB Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
47554 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
35555 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
27091 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
317083 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
104157 usd
CY2024Q3 us-gaap Fee Income
FeeIncome
700000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
500000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
600000 usd
CY2024Q3 us-gaap Interest Income Expense After Provision For Loan Loss
InterestIncomeExpenseAfterProvisionForLoanLoss
100000 usd
CY2023Q3 us-gaap Interest Income Expense After Provision For Loan Loss
InterestIncomeExpenseAfterProvisionForLoanLoss
0 usd
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0462 pure
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.60 pure
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2319048 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.00
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2319048 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.00
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
903994 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.15
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2100000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
300000 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
200000 usd
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4583698 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4319543 shares
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4583698 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4319543 shares
CY2024Q3 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1000000 usd
CY2024Q3 us-gaap Grants Receivable
GrantsReceivable
200000 usd
CY2024Q3 ANEB Grant Income Other
GrantIncomeOther
200000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-045151-index-headers.html Edgar Link pending
0001493152-24-045151-index.html Edgar Link pending
0001493152-24-045151.txt Edgar Link pending
0001493152-24-045151-xbrl.zip Edgar Link pending
aneb-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
aneb-20240930_def.xml Edgar Link unprocessable
aneb-20240930_lab.xml Edgar Link unprocessable
aneb-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
Show.js Edgar Link pending
aneb-20240930_cal.xml Edgar Link unprocessable